About this resource:
Source: The Cochrane Collaborative
Last Reviewed: June 2017
Workgroups: Arthritis Workgroup
This Cochrane systematic review assesses the benefits and harms of celecoxib, a selective non-steroidal anti-inflammatory drug (NSAID), in people with rheumatoid arthritis. This systematic review included 8 randomized control trials with durations of 4 to 24 weeks, published between 1998 and 2014, that involved a total of 3,988 adults (mean age = 54 years), most of whom were women (73%), and found that celecoxib may improve clinical symptoms, alleviate pain, and contribute to little or no difference in physical function compared with placebo.
Suggested Citation
Fidahic, M., Jelicic Kadic, A., Radic, M. & Puljak, L. Celecoxib for rheumatoid arthritis. Cochrane Database of Systematic Reviews, 2017 (6). DOI: 10.1002/14651858.CD012095.pub2.